Skip to main content
$9.62 $0.06 (0.6%)

04:00 PM EDT on 03/31/23

Viatris, Inc. (NASDAQ:VTRS)

CAPS Rating: 4 out of 5

The Company develops, licenses, manufactures, markets and distributes generic, brand and branded generic pharmaceutical products and active pharmaceutical ingredients.

Current Price $9.62 Mkt Cap $11.5B
Open $9.59 P/E Ratio 69.39
Prev. Close $9.62 Div. (Yield) $0.48 (5.0%)
Daily Range $9.56 - $9.71 Volume 13,248,480
52-Wk Range $8.42 - $12.40 Avg. Daily Vol. 9,316,925

Caps

How do you think NASDAQ:VTRS will perform against the market?

Add Stock to CAPS Watchlist

All Players

628 Outperform
46 Underperform
 

All-Star Players

116 Outperform
6 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VTRS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

ruinas (< 20)
Submitted September 25, 2015

continued improving earnings as patents expired for big pharma

DouglasRich (< 20)
Submitted January 29, 2008

Mylan is known for making good quality, reliable generic pharmaceutical products, but I think their primary drawback is they haven't found a way to outcompete the generic market. In the pharmacy, cheaper generics are preferred to Mylan's oftentimes… More

Recent Community Commentary

Read the most recent pitches from players about VTRS.

Recs

0
Member Avatar Foolishwisegirl1 (< 20) Submitted: 5/9/2022 11:09:12 AM : Outperform Start Price: $10.34 NASDAQ:VTRS Score: -8.92

Why is this a great stock?

Recs

0
Member Avatar JTPigskin (< 20) Submitted: 3/18/2022 5:42:48 AM : Outperform Start Price: $9.75 NASDAQ:VTRS Score: -0.70

Push for cheaper and generic drugs will drive their sales

Recs

0
Member Avatar TMFkodyk123 (56.71) Submitted: 7/30/2021 2:22:42 PM : Outperform Start Price: $13.70 NASDAQ:VTRS Score: -23.17

The FDA's approval of Viatris and Biocon's Lantus insulin biosimilar, Semglee, will reach countless Americans and generate a couple hundred million dollars in annual revenue. More importantly, the FDA's approval is an indication of things to come as it relates to biosimilars, which should be big business for Viatris.

Leaderboard

Find the members with the highest scoring picks in VTRS.

Score Leader

heftyjeffy

heftyjeffy (< 20) Score: +404.12

The Score Leader is the player with the highest score across all their picks in VTRS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
heftyjeffy < 20 1/26/2009 Underperform 1Y $10.31 -6.98% +397.14% +404.12 0 Comment
SpecBull 75.42 5/1/2009 5/17/2009 Underperform 3W $12.78 -24.94% +371.90% +396.85 0 Comment
alley11 < 20 5/1/2009 Underperform 3W $12.78 -24.94% +371.90% +396.85 0 Comment
GenericMike 24.54 7/10/2009 Underperform 3M $11.64 -17.60% +367.01% +384.62 0 Comment
wcwhiner 27.47 7/23/2009 Underperform 5Y $12.83 -25.28% +319.22% +344.50 0 Comment
aguacer0 26.96 7/28/2009 Underperform 3W $12.14 -20.98% +318.87% +339.86 0 Comment
Spelunkin 26.07 11/5/2009 Underperform 5Y $16.26 -41.01% +286.48% +327.50 0 Comment
TrackDuality < 20 11/6/2009 Underperform 5Y $16.53 -41.97% +284.30% +326.27 0 Comment
GoodbyeForNow 98.59 10/8/2009 Underperform 5Y $16.02 -40.13% +283.26% +323.39 0 Comment
TrackCarter 22.13 9/21/2009 Underperform 3M $15.23 -37.05% +285.65% +322.70 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VTRS.